Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multi-Center Open-Label Clinical Trial to Assess the Prevention of Liver Transplantation and/or Death Among Subjects Treated With Intravenous Silibinin (Legalon® SIL) for Amatoxin Induced Hepatic Failure

NCT00915681 is registered in ClinicalTrials.gov with Mylan Specialty, LP as lead sponsor.

NCT NCT00915681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00915681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multi-Center Open-Label Clinical Trial to Assess the Prevention of Liver Transplantation and/or Death Among Subjects Treated With Intravenous Silibinin (Legalon® SIL) for Amatoxin Induced Hepatic Failure
Lead sponsor
Mylan Specialty, LP
Phase
Phase 2
Overall status
Terminated
Start date
November 10, 2009
Completion date
April 10, 2020
Enrollment
148 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

amanita poisoning, amatoxin poisoning, liver failure, mushroom poisoning